{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:38:47Z","timestamp":1794335927507,"version":"4.9.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12350-022-02986-7","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T21:53:01Z","timestamp":1657576381000},"page":"357-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?"],"prefix":"10.1016","volume":"30","author":[{"given":"Tim","family":"Wollenweber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kretschmer-Chott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Wurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sazan","family":"Rasul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Kulterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Rettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bonderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Traub-Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-022-02986-7_bib1","first-page":"214","article-title":"Systemic amyloidosis","volume":"6","author":"Lachmann","year":"2006","journal-title":"Cardiavascular Ren."},{"key":"10.1007\/s12350-022-02986-7_bib2","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib3","doi-asserted-by":"crossref","first-page":"11793","DOI":"10.1016\/S0021-9258(17)39100-7","article-title":"Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat","volume":"260","author":"Soprano","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1007\/s12350-022-02986-7_bib4","doi-asserted-by":"crossref","first-page":"27207","DOI":"10.1074\/jbc.M101024200","article-title":"Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants","volume":"276","author":"Quintas","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1007\/s12350-022-02986-7_bib5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants, 2003","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"key":"10.1007\/s12350-022-02986-7_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.recesp.2011.05.003","article-title":"Also a Heart Disease","volume":"64","author":"Garc\u00eda-Pav\u00eda","year":"2011","journal-title":"Rev Esp Cardiol Engl Ed"},{"key":"10.1007\/s12350-022-02986-7_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/modpathol.2014.102","article-title":"Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis","volume":"28","author":"Yanagisawa","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1007\/s12350-022-02986-7_bib9","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: A prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1007\/s12350-022-02986-7_bib11","first-page":"391","article-title":"Senile systemic amyloidosis","volume":"117","author":"Pitk\u00e4nen","year":"1984","journal-title":"Am J Pathol"},{"key":"10.1007\/s12350-022-02986-7_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s12350-022-02986-7_bib13","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s12350-022-02986-7_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0046-8177(91)90227-G","article-title":"Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: A clinicopathologic, histochemical, immunohistochemical, and ultrastructural study","volume":"22","author":"Takahashi","year":"1991","journal-title":"Hum Pathol"},{"key":"10.1007\/s12350-022-02986-7_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jnnp.41.9.847","article-title":"Electroneurophysiological studies in familial amyloid polyneuropathy\u2013Portuguese type","volume":"41","author":"Lu\u00eds","year":"1978","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s12350-022-02986-7_bib16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-022-02986-7_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/13506129.2013.871250","article-title":"Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis","volume":"21","author":"Glaudemans","year":"2014","journal-title":"Amyloid"},{"key":"10.1007\/s12350-022-02986-7_bib19","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1007\/s12350-022-02986-7_bib20","first-page":"54","article-title":"Pathophysiologic considerations and clinicopathological correlates of technetium-99m stannous pyrophosphate myocardial scintigraphy","volume":"10","author":"Willerson","year":"1980","journal-title":"Cardiovasc Nucl Med"},{"key":"10.1007\/s12350-022-02986-7_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","article-title":"Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: Implications for utilizing nuclear medicine studies to subtype amyloidosis","volume":"25","author":"Stats","year":"2016","journal-title":"Cardiovasc Pathol"},{"key":"10.1007\/s12350-022-02986-7_bib22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1007\/s12350-022-02986-7_bib23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijcard.2017.10.027","article-title":"Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon","volume":"254","author":"Cappelli","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib24","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2\u2014Evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-022-02986-7_bib25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0039-1688978","article-title":"Diabetic neuropathy","volume":"39","author":"Zakin","year":"2019","journal-title":"Semin Neurol"},{"key":"10.1007\/s12350-022-02986-7_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00108-020-00770-8","article-title":"Diabetic polyneuropathy","volume":"61","author":"Ziegler","year":"2020","journal-title":"Internist"},{"key":"10.1007\/s12350-022-02986-7_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-022-02986-7_bib28","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1007\/s12350-022-02986-7_bib29","first-page":"78","article-title":"Tegsedi (Inotersen): An antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharm Basel Switz"},{"key":"10.1007\/s12350-022-02986-7_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-022-02986-7_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.pneurobio.2003.11.002","article-title":"Neurodegeneration in familial amyloid polyneuropathy: From pathology to molecular signaling","volume":"71","author":"Sousa","year":"2003","journal-title":"Prog Neurobiol"},{"key":"10.1007\/s12350-022-02986-7_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","article-title":"Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis","volume":"25","author":"Ross","year":"2018","journal-title":"Amyloid"},{"key":"10.1007\/s12350-022-02986-7_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9113446","article-title":"In vivo quantification of myocardial amyloid deposits in patients with suspected transthy","volume":"9","author":"Wollenweber","year":"2020","journal-title":"J Clin Med"},{"key":"10.1007\/s12350-022-02986-7_bib34","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD quantification in cardiac amyloidosis: A novel imaging biomarker","volume":"13","author":"Scully","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-022-02986-7_bib35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13023-020-01565-8","article-title":"Abdominal fat pad biopsies exhibit good diagnostic accuracy in patients with suspected transthyretin amyloidosis","volume":"15","author":"Paulsson Rokke","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s12350-022-02986-7_bib36","article-title":"Amyloid deposit corresponds to technetium-99m-pyrophosphate accumulation in abdominal fat of patients with transthyretin cardiac amyloidosis","author":"Takahashi","year":"2021","journal-title":"J Nucl Cardiol Off Publ Am Soc Nucl Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib37","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib38","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-022-02986-7_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/hrt.52.3.321","article-title":"Non-invasive assessment of the presence and severity of cardiac amyloidosis: A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy","volume":"52","author":"Eriksson","year":"1984","journal-title":"Br Heart J"},{"key":"10.1007\/s12350-022-02986-7_bib40","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1007\/s12350-017-1166-7","article-title":"Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis","volume":"26","author":"Sperry","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biomedicines7010011","article-title":"Ultrastructure in transthyretin amyloidosis: From pathophysiology to therapeutic insights","volume":"7","author":"Koike","year":"2019","journal-title":"Biomedicines"},{"key":"10.1007\/s12350-022-02986-7_bib42","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/msj.21352","article-title":"Amyloid neuropathies","volume":"79","author":"Shin","year":"2012","journal-title":"Mt Sinai J Med NY"},{"key":"10.1007\/s12350-022-02986-7_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","article-title":"Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis","volume":"216","author":"Ihse","year":"2008","journal-title":"J Pathol"},{"key":"10.1007\/s12350-022-02986-7_bib44","first-page":"63","article-title":"Heart complications in familial transthyretin amyloidosis: Impact of age and gender","volume":"17","author":"H\u00f6rnsten","year":"2010","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"key":"10.1007\/s12350-022-02986-7_bib45","first-page":"240","article-title":"Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)","volume":"25","author":"Pilebro","year":"2018","journal-title":"J Nucl Cardiol Off Publ Am Soc Nucl Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Ups J Med Sci"},{"key":"10.1007\/s12350-022-02986-7_bib47","article-title":"Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis","author":"Roshankar","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib48","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-022-02986-7_bib49","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s12350-021-02563-4","article-title":"Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis","volume":"28","author":"Miller","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib50","article-title":"Quantitation of myocardial 99mTc-HMDP uptake with new SPECT\/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use?","author":"Bellevre","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-022-02986-7_bib51","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: Where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s12350-022-02986-7_bib52","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.3390\/jcm9072234","article-title":"Hereditary ATTR amyloidosis in Austria: Prevalence and epidemiological hot spots","volume":"9","author":"Auer-Grumbach","year":"2020","journal-title":"J Clin Med"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-022-02986-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-022-02986-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123000776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123000776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-022-02986-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T15:38:47Z","timestamp":1735573127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1071358123000776"],"URL":"https:\/\/doi.org\/10.1007\/s12350-022-02986-7","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-022-02986-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 THE AUTHORS. Published by ELSEVIER INC. on behalf of American Society of Nuclear Cardiology. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}